Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Double Dose of Tamiflu Offers No Added Benefit in Severe Flu

Published: Tuesday, June 04, 2013
Last Updated: Tuesday, June 04, 2013
Bookmark and Share
Early treatment with Tamiflu is beneficial for patients with uncomplicated flu infection.

Giving double doses of the antiviral drug Tamiflu to patients admitted to hospital with severe flu offers no clinical advantage over the standard dose, according to a randomized trial involving Oxford University researchers based in South East Asia.

This is the first study to look at the effectiveness of higher doses of Tamiflu, or oseltamivir, in cases of severe influenza infection.

The findings have implications for global guidelines on clinical management of severe flu, and also the stockpiling of drugs by national governments for pandemic preparedness, including in the current outbreak of the H7N9 bird flu virus in China.

Professor Jeremy Farrar, head of the Oxford University Clinical Research Unit in Vietnam and director of the South East Asia Infectious Disease Clinical Research Network, led the research. He said: 'The recommendation to give higher doses of oseltamivir to severe cases of flu infection has major implications for clinical management, public health, and planning for antiviral stockpiles but has not been grounded in evidence. Our findings do not support routine use of double doses to treat severe flu infections, which could help to conserve drug stocks in the event of a pandemic.'

The study is published in the medical journal BMJ and was funded by the Wellcome Trust, US National Institute of Allergy and Infectious Diseases and the Singapore National Medical Research Council.

Most people who are infected with flu will recover in a few days or up to two weeks. But some people will develop complications, such as difficulty with breathing, that result in hospital admission and can be life-threatening.

Studies have found that early treatment with Tamiflu is beneficial for patients with uncomplicated flu infection and improves survival in hospitalized patients with severe infection. This has led some authorities to recommend double doses of the drug for treatment of patients with severe flu infections.

The new study was conducted by researchers from the South East Asia Infectious Diseases Clinical Research Network, including scientists from Oxford University clinical research units in Indonesia, Thailand and Vietnam.

The trial involved 326 patients with severe flu infection at 13 hospitals in Indonesia, Singapore, Thailand and Vietnam. Most of the patients were children under the age of 15.

Patients were given either a standard dose or double dose of Tamiflu for five days. Their virus levels were monitored for the duration of the treatment along with other outcomes, such as admission to intensive care, the need for mechanical ventilation to assist with breathing and death.

The findings reveal no difference in virus levels at day five between the different doses. There were also no clinical differences in the outcomes for patients, including need for ventilation, time in hospital, deaths, or rates of adverse events.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
Thursday, July 16, 2015
New Vaccine Generates Strong Immune Response Against Hepatitis C
A new hepatitis C vaccine has shown promising results in an early clinical trial at Oxford University, generating strong and broad immune responses against the virus causing the disease.
Friday, November 07, 2014
UK Scientists to Begin Trial of Potential HIV Cure
Scientists and clinicians from five leading UK universities will begin a groundbreaking clinical trial next year to test a possible cure for HIV infection.
Tuesday, November 26, 2013
Capturing Cancer Cells
When dealing with cancer, time is critical. Identifying cancer before it spreads can often be the difference between life and death, so early diagnosis is key.
Thursday, February 28, 2013
Key Molecule Could Reveal Many Cancers Early On
A technique for monitoring high levels of a protein found in many pre-cancerous cell types – including breast, lung and skin cancer – could be used to detect cancer early.
Wednesday, November 07, 2012
First Trial of a New Hepatitis C Vaccine Shows Promise
A new vaccine against the chronic liver disease hepatitis C has shown promising results in a first clinical trial in humans, Oxford University researchers report.
Thursday, January 05, 2012
Scientific News
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Immune System 'On Switch' Breakthrough Could Lead to Targeted Drugs
A crucial 'on switch' that boosts the body's defenses against infections has been successfully identified in new scientific research.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!